Customer Reviews

US Department of Health and Human Services (HHS) - Patent US6630507B1

"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3."

Read Entire Patent 507

Leave A Review For CBD Global

Leave A Review

A truly reliable company in the cannabis space!

May 24, 2020

These guys go above and beyond from their products and formulations to their customer support, standardization practices, and documentation. They’ve been a key partner in helping us with our online CBD e-commerce store providing us with all necessary documents when needed, high-quality branded products, and team support. I highly recommend working with CBD Global!!

Dustin ~ ReleafCBD.com

See All Reviews

EDITING TECHNIQUES USED

Genome sequencing of specific cannabis strains

Genome sequencing of specific cannabinoids (THC-A Synthase)

Chemical Mutanagenesis

Gene Gun Editing

Agrobacterium Mediated Transformation

Hemoscreen™ Summary

(Cannabinoid Blood Tests)

This convenient and portable blood test kit is designed for clinical environments and for use by healthcare practitioners assisting and monitoring patient volunteers. Hemoscreen™ measures bioavailable absorption rates of medications and their associated blood concentration levels over time. These absorption rates change based on the delivery method of each unique product.

The first correlation of data associates a product to its measured max absorption. The second data set completes the bell curve showing the longevity and half-life of cannabinoids within the blood. The combined data is used to establish the most reasonably accurate dosage and regimen plans for patients that the cannabis industry has seen to date.

Hemoscreen™ is providing valuable information to further improve the ongoing development of efficacious cannabinoid medications.

Prague Facility

Extraction Science

Our exclusive European partnership provides direct access to:

A Schedule 1 Controlled Substance Licensed facility.

A sister Pharmaceutical research company for conducting clinical trials on cannabinoids and medical devices.

Standardized production of new Minor-Cannabinoid Predominant (MCP) oils and isolates (CBG, CBC, CBN, CBDV).

Synthetic CBD, CBC, and semi-synthetic CBN for research APIs.

An entire department of cannabis chemists focused on cutting edge research and innovation.

Close relationships with state authorities and regulators.

TrueNano™ Backscatter Sample Test Results

True Nano Water BackScatter Test 1 CBD Global

True Nano Water BackScatter Test 2 CBD Global

Research & Development

Education
Academic Collaboration
Genetic Species Development
Cell Culturing
Tissue Propagation
Clinical Studies & Patient Monitoring
Data Collection & Evaluation For Future R&D

Product Formulation

Research Data Analysis to Product Concept
Formulation & Production
Transparency Batch Tracking
In House Design & Development
In House Marketing & PR
Sales & Distribution (Wholesale & Retail)

Radioligand Binding Summary

(CB1/CB2 receptor binding affinity of cannabinoids)

The binding affinity of cannabinoids to their respective cell surface receptors (CB1/CB2) is being measured by using existing techniques of binding ligand molecules to cannabinoids and following them to specific, targeted sites. Successful binding is determined electrochemically or through fluorescence detection method. This form of analytic test identifies the presence of target molecules in a sample known to bind to receptors of interest.

This procedure is being utilized to identify any potential changes in binding affinity that may be caused by the differences between a patient receiving natural phytocannabinoids vs. derivative salts, isomers or synthesized versions. Additionally, changes in cellular metabolism may be seen between species of cannabis and their associated full plant spectrums.

Ultimately, this allows for the most accurate means of mapping specific forms of disease to patient demographics and the treatment values of different cannabis plant species. Physicians and health care practitioners can be better equipped to align and recommend the appropriate cannabis phenotype profiles for specific medicines needed by each unique patient.

Analytics & Testing

Pre/Post Harvest Potency Testing
Oils & Isolates Full Panel Testing (Potency, Solvents, Pesticides, Microbials, Metals)
Water Soluble Powders & Liquids Potency Testing
Finished Consumer Goods Potency Testing
Nano Particle Size Testing
Terpene Testing
2-AG/Anandamide, CBD/THC Metabolite Blood Analysis
Radioligand Binding Assays